user

Pramlintide as an adjunct to insulin glargine reduced A1C and body weight in patients with type 2 diabetes

被引：0
|
作者：
Frias, Juan
Bei, Zhang
Darsow, Tamara
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A112 / A112
页数：1
相关论文
共 50 条
  • [31] Diabetes Distress and Its Association with Clinical Outcomes in Patients with Type 2 Diabetes Treated with Pramlintide as an Adjunct to Insulin Therapy
    Peyrot, Mark
    Rubin, Richard R.
    Polonsky, William H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2008, 10 (06) : 461 - 466
  • [32] Initiation of insulin glargine versus lifestyle management in people with type 2 diabetes and A1c of 7-8%
    Blickle, Jean-Frederic
    Hancu, Nicolae
    Piletic, Milivoj
    Profozic, Velimir
    Shestakova, Marina
    Dain, Marie-Paule
    Jacqueminet, Sophie
    Grimaldi, Andre
    DIABETES, 2008, 57 : A139 - A140
  • [33] Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
    Hollander, P
    Maggs, DG
    Ruggles, JA
    Fineman, M
    Shen, L
    Kolterman, OG
    Weyer, C
    OBESITY RESEARCH, 2004, 12 (04): : 661 - 668
  • [34] The addition of insulin glargine to lower hypoglycemic events and A1C levels in children and adolescents with type 1 diabetes
    Dixon, B
    Chase, HP
    Fiallo-Scharer, R
    Walravens, P
    Klingen-Smith, G
    Rewers, M
    Garg, S
    DIABETES, 2003, 52 : A400 - A400
  • [35] Switching to insulin glargine treatment improves hemoglobin A1c levels in children and adolescents with type 1 diabetes
    Cetinkaya, Ergun
    Kibar, Ayse Esin
    Aycan, Zehra
    Vidinlisan, Sadi
    Gurbuz, Fatih
    Cakyr, Bahar
    HORMONE RESEARCH, 2006, 65 : 59 - 59
  • [36] Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks
    Gottlieb, A
    Velte, M
    Fineman, M
    Kolterman, O
    DIABETES, 2000, 49 : A109 - A109
  • [37] Amylin replacement with pramlintide as an adjunct to insulin therapy facilitates a combined improvement in glycemic and weight control in type 2 diabetes.
    Maggs, DG
    Weyer, C
    Burrell, T
    Gottlieb, AD
    Shen, LZ
    Kolterman, OG
    DIABETOLOGIA, 2001, 44 : A237 - A237
  • [38] Amylin replacement with pramlintide as an adjunct to insulin therapy facilitates a combined improvement in glycemic and weight control in type 2 diabetes.
    Maggs, DG
    Weyer, C
    Burrell, T
    Gottlieb, AD
    Shen, LZ
    Kolterman, OG
    DIABETOLOGIA, 2001, 44 : A237 - A237
  • [39] Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 2 diabetes during treatment for 52 weeks
    Fineman, M
    Gottlieb, A
    Skare, S
    Kolterman, O
    DIABETES, 2000, 49 : A106 - A106
  • [40] Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes - A 1-year randomized controlled trial
    Hollander, PA
    Levy, P
    Fineman, M
    Maggs, DG
    Shen, LZ
    Strobel, SA
    Weyer, C
    Kolterman, OG
    DIABETES CARE, 2003, 26 (03) : 784 - 790
12345